00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest T cells engineered to express an anti-PSCA chimeric antigen receptor (CAR) and TGFβ-RII- and CD124-based fusion proteins could help treat pancreatic cancer. The CAR T cells...
15:34 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sutro, Merck partner to develop immune modulators

Sutro Biopharma Inc. (South San Francisco, Calif.) is collaborating with Merck & Co. Inc. (NYSE:MRK) to discover and develop immune modulators to treat cancer and autoimmune diseases. Sutro is to receive $60 million up front from...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture and mouse studies suggest miR-138 or its mimetics could help treat Pseudomonas aeruginosa lung infections. In lung samples from a mouse model of P. aeruginosa lung infection, levels of miR-138 were higher...
20:08 , Jul 24, 2018 |  BC Extra  |  Company News

Sutro, Merck partner to develop immune modulators

Sutro Biopharma Inc. (South San Francisco, Calif.) is collaborating with Merck & Co. Inc. (NYSE:MRK) to discover and develop immune modulators to treat cancer and autoimmune diseases. Sutro is to receive $60 million up front from...
22:53 , Jul 20, 2018 |  BC Extra  |  Preclinical News

RIPK1 mutations in humans linked to IBD, arthritis

A study published in Science provides the first glimpse of clinical outcomes of receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) deficiency in humans, a target sought after by at least two companies trying to curb its...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
17:37 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer, melanoma, lung cancer Mouse studies suggest a phospholipid-conjugated TLR7 agonist could help treat metastatic breast cancer, melanoma and lung cancer. The conjugate consists of a previously identified purine-based TLR7 agonist linked to dioleoylglycerophosphoethanolamine...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on June 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...